Rituximab preserves vision in ocular mucous membrane pemphigoid

Bibliography

• Rubsam A, Klein JP, Pleyer U. Ocular cicatricial pemphigoid - state of the art in clinic and therapy for a problematic disease. Klin Monatsbl Augenheilkd 2013;230:796-803
   PubMed Web of Science ®Google Scholar
• Dart JK, Saw PJ. Immune Modulation in Ocular Mucous Membrane Pemphigoid. Immune modulation and anti-inflammatory therapy in ocular disorders. Springer Verlag, Heidelberg 2014;1:19-39
   Google Scholar
• Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010;117:861-9
   PubMed Web of Science ®Google Scholar
• Prey S, Robert PY, Drouet M, et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol 2007;87:74-5
   PubMed Web of Science ®Google Scholar
• Nigam R, Levitt J. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease? J Drugs Dermatol 2012;11:622-5
   PubMed Web of Science ®Google Scholar
• Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9
   PubMed Web of Science ®Google Scholar
• Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20
   PubMed Web of Science ®Google Scholar
• Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 2012;68:499-506
   PubMed Web of Science ®Google Scholar
• Tauber J, Jabbur N, Foster CS. Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea 1992;5:446
   Google Scholar
• Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002;138:370-9
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011;65:552-8
   PubMed Web of Science ®Google Scholar
• Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011;147:843-9
   PubMed Web of Science ®Google Scholar
• Wollina U, Koch A, Hansel G. Rituximab therapy of recalcitrant bullous dermatoses. J Dermatol Case Rep 2008;2:4-7
   Google Scholar
• Schumann T, Schmidt E, Booken N, et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol 2002;89:101-2
   Google Scholar
• Schmidt E, Seitz CS, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007;156:352-6
   PubMed Web of Science ®Google Scholar
• Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2011;25:1238-40
   PubMed Web of Science ®Google Scholar
• Taverna JA, Lerner A, Bhawan J, et al. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 2007;6:731-2
   PubMedGoogle Scholar
• Sitaru C, Thiel J. The need for markers and predictors of Rituximab treatment Resistance. Exp Dermatol 2014
   Google Scholar
• Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993-9
   Google Scholar
• Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol 2008;7:529-41
   Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73
   PubMed Web of Science ®Google Scholar
• Kong JS, Teuber SS, Gershwin ME. Potential adverse events with biologic response modifiers. Autoimmun Rev 2006;5:471-85
   PubMed Web of Science ®Google Scholar
• Zone JJ. Taking responsibility for complex medical dermatology patient management. Arch Dermatol 2011;147:850
   PubMed Web of Science ®Google Scholar
• Saadoun D, Bodaghi B, Bienvenu B, et al. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2011;12:774-83
   Web of Science ®Google Scholar
• Renard D, Cornillet L, Castelnovo G. Myocardial infarction after rituximab infusion. Neuromuscul Disord 2003;23:599-601
   Google Scholar